← All organizations

Ridgeback Biotherapeutics, LP

For profitWebsite ↗

Also known as: RIDGEBACK BIOTHERAPEUTICS | Ridgeback Biotherapeutics, LP

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

First marketed drug

Last known activity

Dec 21, 2020

Timeline

2010s

Jun 1, 2016
Ridgeback Biotherapeutics, LP— Founded

2020s

Dec 21, 2020
ANSUVIMAB— Marketing Organization

Drugs by trial phase (2 distinct, 4 trials)

Phase 2 (1 own, 0 via acquisition)

Molnupiravir

Other trials (1 own, 0 via acquisition)

ANSUVIMAB

Indications

Studied for

Marketed drugs (1)

ANSUVIMAB

Recent trials (4)

NCT05067166Lead sponsorN/A—
NCT04405739Lead sponsorPhase 2May 26, 2020
NCT04405570Lead sponsorPhase 2May 26, 2020
NCT04392219Lead sponsorPhase 1Apr 10, 2020

Details

Founded: Miami, FL, US Jun 1, 2016
Last known activity: Dec 21, 2020